Evidence map›Paper›PMID 35931690›Full record

ArticleNature communications2022

Regulatory mechanisms of lipopolysaccharide synthesis in Escherichia coli.

Sheng Shu, Wei Mi

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Loss of O-antigen due toScience advances · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Essential Role of LapD in the Absence of Cardiolipins.International journal of molecular sciences · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. AcuteMicroorganisms · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sheng ShuDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA.
Wei MiDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA. wei.mi@yale.edu.ORCID http://orcid.org/0000-0002-2845-4608
Yale University · US

Funding

High-throughput electron cryo-microscopeS10OD023603 · OD · YALE UNIVERSITY · PI SIGWORTH, FREDERICK J · 2018 to 2018
$1.9M
Molecular Mechanisms of the Type I Secretion System from Bacterial PathogensR01GM137068 · NIGMS · YALE UNIVERSITY · PI MI, WEI · 2021 to 2025
$1.9M
NIGMS NIH HHS R01 GM137068NIH HHS S10 OD023603
6 · The paper itself

Abstract

Lipopolysaccharide (LPS) is an essential glycolipid and forms a protective permeability barrier for most Gram-negative bacteria. In E. coli, LPS levels are under feedback control, achieved by FtsH-mediated degradation of LpxC, which catalyzes the first committed step in LPS synthesis. FtsH is a membrane-bound AAA+ protease, and its protease activity toward LpxC is regulated by essential membrane proteins LapB and YejM. However, the regulatory mechanisms are elusive. We establish an in vitro assay to analyze the kinetics of LpxC degradation and demonstrate that LapB is an adaptor protein that utilizes its transmembrane helix to interact with FtsH and its cytoplasmic domains to recruit LpxC. Our YejM/LapB complex structure reveals that YejM is an anti-adaptor protein, competing with FtsH for LapB to inhibit LpxC degradation. Structural analysis unravels that LapB and LPS have overlapping binding sites in YejM. Thus, LPS levels control formation of the YejM/LapB complex to determine LpxC protein levels.

Indexed as

Escherichia coliEscherichia coli ProteinsAmidohydrolasesGram-Negative BacteriaLipopolysaccharidesMembrane ProteinsAmidohydrolasesEscherichia coli ProteinsLipopolysaccharidesMembrane ProteinsYejM protein, E coli

Identifiers

PMID35931690
PMCPMC9356133
OpenAlexW4289918774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.